BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20206173)

  • 1. Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer.
    Schumacher B; Mondry J; Thiel P; Weyand M; Ottmann C
    FEBS Lett; 2010 Apr; 584(8):1443-8. PubMed ID: 20206173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
    Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
    Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
    Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
    Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of p53 activity through lysine methylation.
    Chuikov S; Kurash JK; Wilson JR; Xiao B; Justin N; Ivanov GS; McKinney K; Tempst P; Prives C; Gamblin SJ; Barlev NA; Reinberg D
    Nature; 2004 Nov; 432(7015):353-60. PubMed ID: 15525938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.
    Okorokov AL; Sherman MB; Plisson C; Grinkevich V; Sigmundsson K; Selivanova G; Milner J; Orlova EV
    EMBO J; 2006 Nov; 25(21):5191-200. PubMed ID: 17053786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation of methionine residue at hydrophobic core destabilizes p53 tetrameric structure.
    Nomura T; Kamada R; Ito I; Chuman Y; Shimohigashi Y; Sakaguchi K
    Biopolymers; 2009 Jan; 91(1):78-84. PubMed ID: 18781628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the human p53 core domain in the absence of DNA.
    Wang Y; Rosengarth A; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):276-81. PubMed ID: 17327663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding.
    Rippin TM; Freund SM; Veprintsev DB; Fersht AR
    J Mol Biol; 2002 May; 319(2):351-8. PubMed ID: 12051912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How p53 binds DNA as a tetramer.
    McLure KG; Lee PW
    EMBO J; 1998 Jun; 17(12):3342-50. PubMed ID: 9628871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling to p53: breaking the posttranslational modification code.
    Appella E; Anderson CW
    Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins--identification of additional interacting regions.
    Iosefson O; Azem A
    FEBS Lett; 2010 Mar; 584(6):1080-4. PubMed ID: 20153329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
    Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
    Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein.
    Bessard AC; Garay E; Lacronique V; Legros Y; Demarquay C; Houque A; Portefaix JM; Granier C; Soussi T
    Oncogene; 1998 Feb; 16(7):883-90. PubMed ID: 9484779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins.
    Longo F; Marchetti MA; Castagnoli L; Battaglia PA; Gigliani F
    Biochem Biophys Res Commun; 1995 Jan; 206(1):326-34. PubMed ID: 7818536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
    Tarunina M; Jenkins JR
    Oncogene; 1993 Nov; 8(11):3165-73. PubMed ID: 8414520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53.
    Hansson LO; Friedler A; Freund S; Rudiger S; Fersht AR
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10305-9. PubMed ID: 12124396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of azurin and C-terminal domain of p53 is mediated by nucleic acids.
    Xu C; Zhao Y; Zhao B
    Arch Biochem Biophys; 2010 Nov; 503(2):223-9. PubMed ID: 20800053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.